Daniel Speidel
Company: Breakpoint Therapeutics
Job title: Managing Director & Co- Founder
Seminars:
Chair’s Opening Remarks 8:25 am
day: Day One
Panel Discussion: What Makes the Perfect Next-Generation DDR Inhibitor Target? 4:30 pm
• How does protein size and function impact small molecule approaches? • Where does pathway redundancy fit into the journey of finding new targets? • Why have next generation targets been less successful moving through clinical phases?Read more
day: Day One
Chair’s Closing Remarks 5:00 pm
day: Day One
Chair’s Opening Remarks 8:50 am
day: Day Two
Chair’s Closing Remarks 4:00 pm
day: Day Two